Auransa, Inc.’s Exclusive Licensing Agreement With China Oncology Focus Limited

Sidley represented Auransa, Inc., an AI-driven pharmaceutical company that is developing precision medicines in areas of significant unmet medical need, in a licensing agreement granting China Oncology Focus (an affiliate of Lee’s Pharmaceutical Holdings Ltd.) exclusive rights to develop and commercialize Auransa’s AU018 in China and other countries of Southeast Asia.

AU018, which is currently in preclinical development, is a potentially best-in-class cardioprotective agent intended to be paired with chemotherapy in the treatment of cancer. The compound was identified by Auransa’s SMarTR™ Engine, the company’s powerful AI-driven computational platform, as part of a project designed to discover drugs capable of mitigating the cardiotoxicity associated with the chemotherapeutic agent doxorubicin, without inhibiting its anti-cancer activity.

Under the terms of the agreement, Auransa will receive an upfront payment, potential future milestone payments and high single-digit royalties on future net sales. In total, Auransa is eligible to receive up to $22.5 million upon the successful attainment of key milestones.

Sidley advised Auransa, Inc. with a team led by Thomas Duley (Picture).

Involved fees earner: Thomas Duley – Sidley Austin LLP;

Law Firms: Sidley Austin LLP;

Clients: Auransa Inc.;

Author: Ambrogio Visconti